Corrias A, Picco P, Einaudi S, de Sanctis L, Besenzon L, Garrè M L, Brach del Prever A, de Sanctis C
Division of Pediatric Endocrinology, Regina Margherita Children's Hospital, Turin, Italy.
J Pediatr Endocrinol Metab. 1997 Jan-Feb;10(1):41-9. doi: 10.1515/jpem.1997.10.1.41.
We assessed the efficacy of GH treatment in 25 GH deficient patients irradiated for brain tumors (eight with glioma cranio-irradiated, eleven with medulloblastoma and six with ependymoma craniospinal-irradiated). We administered GH at doses of 0.6-0.9 IU/kg/week for one to three years at least two years after diagnosis of the tumor. We assessed the efficacy of the treatment each year by comparing the values of height velocity over bone age and change in the ratios progression of chronological age/progression of bone age and progression of statural age/progression of bone age. The treatment promoted satisfactory growth; better results were obtained in patients with glioma, who received cranial irradiation only, than in those with medulloblastoma or ependymoma, who received spinal irradiation as well. Moreover, the growth prognosis improved, especially in the cranio-irradiated patients. In our series of patients four presented tumor recurrence; these results did not differ significantly from those in irradiated patients with cerebral tumors who were not treated with GH.
我们评估了生长激素（GH）治疗25例因脑肿瘤接受放疗的生长激素缺乏患者的疗效（8例为颅部放疗的胶质瘤患者，11例为髓母细胞瘤患者，6例为颅脊柱放疗的室管膜瘤患者）。在肿瘤诊断至少两年后，我们以0.6 - 0.9 IU/kg/周的剂量给予生长激素，持续一至三年。我们每年通过比较身高生长速度相对于骨龄的值，以及实际年龄进展/骨龄进展和身高年龄进展/骨龄进展的比值变化来评估治疗效果。该治疗促进了令人满意的生长；仅接受颅部放疗的胶质瘤患者比同时接受脊柱放疗的髓母细胞瘤或室管膜瘤患者取得了更好的效果。此外，生长预后得到改善，尤其是在接受颅部放疗的患者中。在我们的患者系列中，有4例出现肿瘤复发；这些结果与未接受生长激素治疗的脑肿瘤放疗患者的结果无显著差异。
